Cellectar Biosciences Sets March 4 Date for Full-Year 2025 Results and Corporate Update

Cellectar Biosciences, Inc. announced that the company will report financial results for the full year ended December 31, 2025, and provide a corporate update on March 4, 2026, at 8:30 a.m. Eastern Time. The conference call toll-free number is 1-800-717-1738, with conference ID 08197, and a webcast will be available. A replay of the corporate presentation will be available on the Events section of the company’s Investor Relations website.

Cellectar Biosciences is a late-stage clinical radiopharmaceutical company focused on the discovery and development of proprietary drugs for the treatment of cancer. The company’s core objective is to leverage its proprietary Phospholipid Drug Conjugate (PDC) delivery platform to develop cancer cell-targeting treatments.

The company’s product pipeline includes lead assets iopofosine I 131, CLR 121125 (CLR 125), and CLR 121225 (CLR 225), along with proprietary preclinical PDC chemotherapeutic programs and multiple partnered PDC assets. Iopofosine I 131 is designed to provide targeted delivery of iodine-131 for hematologic and solid tumor cancers such as Waldenstrom’s macroglobulinemia and pediatric high grade gliomas.

Iopofosine I 131 has been studied in Phase 2b trials for relapsed or refractory Waldenstrom’s macroglobulinemia and multiple myeloma, non-Hodgkin’s lymphomas, and central nervous system lymphoma, and in the CLOVER-2 Phase 1b study targeting pediatric patients with high-grade gliomas. The FDA has granted iopofosine I 131 Breakthrough Therapy, six Orphan Drug, five Rare Pediatric Drug, and two Fast Track designations for various cancer indications, and the European Medicines Agency has granted PRIME and orphan drug designations for the treatment of Waldenstrom’s macroglobulinemia.